<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37788720</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN><JournalIssue CitedMedium="Internet"><Volume>337</Volume><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Virus research</Title><ISOAbbreviation>Virus Res</ISOAbbreviation></Journal><ArticleTitle>An enterovirus A71 virus-like particle with replaced loops confers partial cross-protection in mice.</ArticleTitle><Pagination><StartPage>199235</StartPage><MedlinePgn>199235</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">199235</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2023.199235</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-1702(23)00197-1</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71), coxsackievirus A16 (CV-A16), and CV-A10 belong to the main prevailing types causing hand-foot-and-mouth disease. Since EV-A71 monovalent vaccine does not confer cross-protection, developing a multivalent vaccine is essential. In this study, a trivalent chimeric virus-like particle of EV-A71 (EV-A71-VLP<sup>CHI3</sup>) was constructed based on EV-A71-VLP backbone by replacing the corresponding surface loops with CV-A16 VP1 G-H, CV-A10 VP1 B-C and E-F loops, which are critical for immunogenic neutralization. The baculovirus-insect cell expression system was employed for EV-A71-VLP<sup>CHI3</sup> production. EV-A71-VLP<sup>CHI3</sup> was purified by sucrose density gradient and observed by transmission electron microscopy. The immunogenicity and protective efficacy of EV-A71-VLP<sup>CHI3</sup> were evaluated in mice. Our results revealed that EV-A71-VLP<sup>CHI3</sup> had a similar morphology to inactivated EV-A71 particles and could induce specific IgG antibodies against EV-A71, CV-A16 and CV-A10 in mice. More importantly, EV-A71-VLP<sup>CHI3</sup> enhanced cross-reactive protection against CV-A16 and CV-A10, by 20 % and 40 %, compared to inactivated EV-A71 counterparts, respectively. In conclusion, the successful construction of EV-A71-VLP<sup>CHI3</sup> suggested that loop-dependent heterologous protection could be transferred by loops replacement on the surface of viral capsid. This strategy may also supplement the development of multivalent vaccines against other infectious viral diseases.</AbstractText><CopyrightInformation>Copyright © 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541100, China; College of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi 541100, China; Key Laboratory of Medical Biotechnology and Translational Medicine, Education Department of Guangxi Zhuang Autonomous Region, Guilin, Guangxi 541100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hanyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541100, China; College of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi 541100, China; Key Laboratory of Medical Biotechnology and Translational Medicine, Education Department of Guangxi Zhuang Autonomous Region, Guilin, Guangxi 541100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi 541100, China; Key Laboratory of Medical Biotechnology and Translational Medicine, Education Department of Guangxi Zhuang Autonomous Region, Guilin, Guangxi 541100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541100, China; Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Wenbian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>College of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi 541100, China; Key Laboratory of Medical Biotechnology and Translational Medicine, Education Department of Guangxi Zhuang Autonomous Region, Guilin, Guangxi 541100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Guochuan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>College of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi 541100, China; Key Laboratory of Medical Biotechnology and Translational Medicine, Education Department of Guangxi Zhuang Autonomous Region, Guilin, Guangxi 541100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Pei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongbo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541100, China; Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541100, China. Electronic address: hbliu@glmc.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qiliang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541100, China; College of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi 541100, China; Key Laboratory of Medical Biotechnology and Translational Medicine, Education Department of Guangxi Zhuang Autonomous Region, Guilin, Guangxi 541100, China. Electronic address: aqua02@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virus Res</MedlineTA><NlmUniqueID>8410979</NlmUniqueID><ISSNLinking>0168-1702</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>16VY3TM7ZO</RegistryNumber><NameOfSubstance UI="C052091">antineoplaston A10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chimeric vaccine</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Hand-foot-and-mouth disease</Keyword><Keyword MajorTopicYN="N">Virus-like particle</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>2</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37788720</ArticleId><ArticleId IdType="pmc">PMC10562737</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2023.199235</ArticleId><ArticleId IdType="pii">S0168-1702(23)00197-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bian L., Gao F., Mao Q., Sun S., Wu X., Liu S., Yang X., Liang Z. Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems. Expert Rev. Anti Infect. Ther. 2019;17(4):233–242. doi: 10.1080/14787210.2019.1585242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2019.1585242</ArticleId><ArticleId IdType="pubmed">30793637</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R.Y., Dong D.Y., Liu R.J., Han J.F., Wang G.C., Zhao H., Li X.F., Deng Y.Q., Zhu S.Y., Wang X.Y., Lin F., Zhang F.J., Chen W., Qin E.D., Qin C.F. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS One. 2013;8(5):e64024. doi: 10.1371/journal.pone.0064024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064024</ArticleId><ArticleId IdType="pmc">PMC3659118</ArticleId><ArticleId IdType="pubmed">23700449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y.K., Chen K.H., Chen K.T. Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: a review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development. Rev. Inst. Med. Trop. Sao Paulo. 2018;60:e70. doi: 10.1590/S1678-9946201860070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1678-9946201860070</ArticleId><ArticleId IdType="pmc">PMC6223252</ArticleId><ArticleId IdType="pubmed">30427405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Yao X.J., Xu S.J., Yang H., Wu C.L., Lu J., Xu W.B., Zhang H.L., Meng J., Zhang Y., He Y.Q., Zhang R.L. Molecular surveillance of coxsackievirus A16 reveals the emergence of a new clade in mainland China. Arch. Virol. 2019;164(3):867–874. doi: 10.1007/s00705-018-4112-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-018-4112-3</ArticleId><ArticleId IdType="pubmed">30498962</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Zhang C., Zhang X., Xiong P., Liu Q., Gong S., Geng L., Zhou D., Huang Z. A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice. Vaccine. 2018;36(5):653–659. doi: 10.1016/j.vaccine.2017.12.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.12.057</ArticleId><ArticleId IdType="pubmed">29295756</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang M., Wang X., Wang Q., Wang Y., Lin J., Sun Y., Li X., Zhang L., Lou Z., Wang J., Rao Z. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell. 2014;5(9):692–703. doi: 10.1007/s13238-014-0087-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0087-3</ArticleId><ArticleId IdType="pmc">PMC4145081</ArticleId><ArticleId IdType="pubmed">24986489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J., Smith A.D., Geisler S.C., Ma X., Arnold G.F., Arnold E. Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1. Structure. 2002;10(7):999–1011. doi: 10.1016/s0969-2126(02)00793-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0969-2126(02)00793-1</ArticleId><ArticleId IdType="pubmed">12121655</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S., Liao Y., Jiang G., Wang L., Zhao H., Yu L., Xu X., Li D., Zhang Y., Li Q. Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally. Vaccine. 2021;39(3):596–604. doi: 10.1016/j.vaccine.2020.11.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.11.070</ArticleId><ArticleId IdType="pubmed">33342637</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C.Y., Liu C.C. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev. Vaccines. 2018;17(9):819–831. doi: 10.1080/14760584.2018.1510326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1510326</ArticleId><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125(1):61–68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorlani A., Forthal D.N. Antibody-dependent enhancement and the risk of HIV infection. Curr. HIV Res. 2013;11(5):421–426. doi: 10.2174/1570162x113116660062.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570162x113116660062</ArticleId><ArticleId IdType="pubmed">24191936</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H., Li Y., Liu G., Jiang Y., Shen S., Bi R., Huang H., Cheng T., Wang C., Wei W. A second open reading frame in human enterovirus determines viral replication in intestinal epithelial cells. Nat. Commun. 2019;10(1):4066. doi: 10.1038/s41467-019-12040-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12040-9</ArticleId><ArticleId IdType="pmc">PMC6731315</ArticleId><ArticleId IdType="pubmed">31492846</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Z., Song Y., Xiao J., Jiang L., Huang W., Wei H., Li J., Zeng H., Yu Q., Li J., Yu D., Zhang Y., Li C., Zhan Z., Shi Y., Xiong Y., Wang X., Ji T., Yang Q., Zhu S., Yan D., Xu W., Zhang Y. Genomic epidemiology of coxsackievirus A16 in mainland of China, 2000-18. Virus Evol. 2020;6(2):veaa084. doi: 10.1093/ve/veaa084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veaa084</ArticleId><ArticleId IdType="pmc">PMC7733612</ArticleId><ArticleId IdType="pubmed">33343924</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., Zhang M., Zhao C., Zheng P., Zhang X., Xu J. From monovalent to multivalent vaccines, the exploration for potential preventive strategies against hand, foot, and mouth disease (HFMD) Virol. Sin. 2021;36(2):167–175. doi: 10.1007/s12250-020-00294-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00294-3</ArticleId><ArticleId IdType="pmc">PMC7525078</ArticleId><ArticleId IdType="pubmed">32997323</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Li K., Wang L., Sun Z., Cao Y., Li P., Sun P., Bao H., Zhou S., Wang S., Bai X., Liu X., Zhao L., Fan X., Liu Z., Lu Z., Yang C., Lou Z. Structures of foot-and-mouth disease virus with bovine neutralizing antibodies reveal the determinant of intraserotype cross-neutralization. J. Virol. 2021;95(24) doi: 10.1128/JVI.01308-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01308-21</ArticleId><ArticleId IdType="pmc">PMC8610593</ArticleId><ArticleId IdType="pubmed">34586859</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y.Q., Chen L., Xu W.B., Yang H., Wang H.Z., Zong W.P., Xian H.X., Chen H.L., Yao X.J., Hu Z.L., Luo M., Zhang H.L., Ma H.W., Cheng J.Q., Feng Q.J., Zhao D.J. Emergence, circulation, and spatiotemporal phylogenetic analysis of coxsackievirus a6- and coxsackievirus a10-associated hand, foot, and mouth disease infections from 2008 to 2012 in Shenzhen, China. J. Clin. Microbiol. 2013;51(11):3560–3566. doi: 10.1128/JCM.01231-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01231-13</ArticleId><ArticleId IdType="pmc">PMC3889734</ArticleId><ArticleId IdType="pubmed">23966496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H., Fan H., Lu P.X., Zhang X.F., Ai J., Shi C., Huo X., Bao C.J., Shan J., Jin Y. Surveillance for severe hand, foot, and mouth disease from 2009 to 2015 in Jiangsu province: epidemiology, etiology, and disease burden. BMC Infect. Dis. 2019;19(1):79. doi: 10.1186/s12879-018-3659-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3659-7</ArticleId><ArticleId IdType="pmc">PMC6341624</ArticleId><ArticleId IdType="pubmed">30669973</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston N.J., Snowden J.S., Martyna A., Shegdar M., Grehan K., Tedcastle A., Pegg E., Fox H., Macadam A.J., Martin J., Hogle J.M., Rowlands D.J., Stonehouse N.J. Production of antigenically stable enterovirus A71 virus-like particles in Pichia pastoris as a vaccine candidate. J. Gen. Virol. 2023;104(6) doi: 10.1099/jgv.0.001867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001867</ArticleId><ArticleId IdType="pmc">PMC10773253</ArticleId><ArticleId IdType="pubmed">37390009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z., Ye X., Huang X., Cai Y., Liu Q., Li Y., Su Z., Huang Z. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8(2):e57601. doi: 10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X., Cai X., Yang Y. Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines. Expert Rev. Vaccines. 2020;19(3):235–246. doi: 10.1080/14760584.2020.1738227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2020.1738227</ArticleId><ArticleId IdType="pubmed">32133886</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H.Y., Han J.F., Qin C.F., Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31(32):3281–3287. doi: 10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H., In H.J., Lee J.A., Sik Yoo J., Lee S.W., Chung G.T., Choi Y.K., Chung J.K., Cho S.J., Lee J.W. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine. 2018;36(24):3445–3452. doi: 10.1016/j.vaccine.2018.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.005</ArticleId><ArticleId IdType="pubmed">29739716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K., He Y.L., Li H.Y., Chen R. Crystal structures of yeast-produced enterovirus 71 and enterovirus 71/coxsackievirus A16 chimeric virus-like particles provide the structural basis for novel vaccine design against hand-foot-and-mouth disease. J. Virol. 2015;89(12):6196–6208. doi: 10.1128/JVI.00422-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00422-15</ArticleId><ArticleId IdType="pmc">PMC4474312</ArticleId><ArticleId IdType="pubmed">25833050</ArticleId></ArticleIdList></Reference><Reference><Citation>Noisumdaeng P., Korkusol A., Prasertsopon J., Sangsiriwut K., Chokephaibulkit K., Mungaomklang A., Thitithanyanont A., Buathong R., Guntapong R., Puthavathana P. Longitudinal study on enterovirus A71 and coxsackievirus A16 genotype/subgenotype replacements in hand, foot and mouth disease patients in Thailand, 2000-2017. Int. J. Infect. Dis. 2019;80:84–91. doi: 10.1016/j.ijid.2018.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2018.12.020</ArticleId><ArticleId IdType="pubmed">30639624</ArticleId></ArticleIdList></Reference><Reference><Citation>Nooraei S., Bahrulolum H., Hoseini Z.S., Katalani C., Hajizade A., Easton A.J., Ahmadian G. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol. 2021;19(1):59. doi: 10.1186/s12951-021-00806-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-021-00806-7</ArticleId><ArticleId IdType="pmc">PMC7905985</ArticleId><ArticleId IdType="pubmed">33632278</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 1938;27(3):493–497. doi: 10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann M.G., He Y., Kuhn R.J. Picornavirus-receptor interactions. Trends Microbiol. 2002;10(7):324–331. doi: 10.1016/s0966-842x(02)02383-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0966-842x(02)02383-1</ArticleId><ArticleId IdType="pubmed">12110211</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz E.M., Jones T.J., Hopkins H.K., Zeng J., Barr K.L. Post-vaccination yellow fever antiserum reduces zika virus in embryoid bodies when placental cells are present. Vaccines. 2020;8(4) doi: 10.3390/vaccines8040752. (Basel)</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8040752</ArticleId><ArticleId IdType="pmc">PMC7768546</ArticleId><ArticleId IdType="pubmed">33322247</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Huang X., Liu Q., Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013;31(17):2130–2136. doi: 10.1016/j.vaccine.2013.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.051</ArticleId><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor A., Foo S.S., Bruzzone R., Dinh L.V., King N.J., Mahalingam S. Fc receptors in antibody-dependent enhancement of viral infections. Immunol. Rev. 2015;268(1):340–364. doi: 10.1111/imr.12367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12367</ArticleId><ArticleId IdType="pmc">PMC7165974</ArticleId><ArticleId IdType="pubmed">26497532</ArticleId></ArticleIdList></Reference><Reference><Citation>Upala P., Apidechkul T., Suttana W., Kullawong N., Tamornpark R., Inta C. Molecular epidemiology and clinical features of hand, foot and mouth disease in northern Thailand in 2016: a prospective cohort study. BMC Infect. Dis. 2018;18(1):630. doi: 10.1186/s12879-018-3560-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3560-4</ArticleId><ArticleId IdType="pmc">PMC6282397</ArticleId><ArticleId IdType="pubmed">30522440</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zhu M., Fang Y., Rong H., Gao L., Liao Q., Zhang L., Dong C. Bioinformatics-based prediction of conformational epitopes for Enterovirus A71 and Coxsackievirus A16. Sci. Rep. 2021;11(1):5701. doi: 10.1038/s41598-021-84891-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84891-6</ArticleId><ArticleId IdType="pmc">PMC7952546</ArticleId><ArticleId IdType="pubmed">33707530</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Ku Z., Dai W., Chen T., Ye X., Zhang C., Zhang Y., Liu Q., Jin X., Huang Z. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice. Vaccine. 2015;33(43):5779–5785. doi: 10.1016/j.vaccine.2015.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.09.043</ArticleId><ArticleId IdType="pubmed">26424606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20(5–6):895–904. doi: 10.1016/s0264-410x(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0264-410x(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Zhai X., Lai Y., Zuo L., Zhang Y., Mei X., Xiang R., Kang Z., Zhou L., Wang H. Construction and immunogenicity of novel chimeric virus-like particles bearing antigens of infectious bronchitis virus and Newcastle disease virus. Viruses. 2019;11(3) doi: 10.3390/v11030254.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11030254</ArticleId><ArticleId IdType="pmc">PMC6465995</ArticleId><ArticleId IdType="pubmed">30871190</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., He D., Yang L., Li Z., Ye X., Yu H., Zhao H., Li S., Yuan L., Qian H., Que Y., Kuo Shih J.W., Zhu H., Li Y., Cheng T., Xia N. A Broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71. Sci. Rep. 2015;5:12973. doi: 10.1038/srep12973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12973</ArticleId><ArticleId IdType="pmc">PMC4525384</ArticleId><ArticleId IdType="pubmed">26243660</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Qian J., Qin L., Li J., Xue C., Ding J., Wang W., Ding W., Yin R., Jin N., Ding Z. Chimeric newcastle disease virus-like particles containing DC-Binding peptide-fused haemagglutinin protect chickens from virulent newcastle disease virus and H9N2 avian influenza virus challenge. Virol. Sin. 2020;35(4):455–467. doi: 10.1007/s12250-020-00199-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00199-1</ArticleId><ArticleId IdType="pmc">PMC7462956</ArticleId><ArticleId IdType="pubmed">32274680</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Liu Y., Li S., Zhao H., Lin Q., Yu H., Huang X., Zheng Q., Cheng T., Xia N. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice. Vaccine. 2016;34(48):5938–5945. doi: 10.1016/j.vaccine.2016.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.018</ArticleId><ArticleId IdType="pubmed">27771182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X., Ku Z., Liu Q., Wang X., Shi J., Zhang Y., Kong L., Cong Y., Huang Z. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J. Virol. 2014;88(1):72–81. doi: 10.1128/JVI.01848-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01848-13</ArticleId><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee P.T.I., Tan S.H., Ong K.C., Tan K.O., Wong K.T., Hassan S.S., Poh C.L. Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice. Sci. Rep. 2019;9(1):4805. doi: 10.1038/s41598-019-41285-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41285-z</ArticleId><ArticleId IdType="pmc">PMC6423319</ArticleId><ArticleId IdType="pubmed">30886246</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Zhang X., Zhang W., Dai W., Xie J., Ye L., Wang H., Chen H., Liu Q., Gong S., Geng L., Huang Z. Enterovirus D68 virus-like particles expressed in Pichia pastoris potently induce neutralizing antibody responses and confer protection against lethal viral infection in mice. Emerg. Microbes Infect. 2018;7(1):3. doi: 10.1038/s41426-017-0005-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-017-0005-x</ArticleId><ArticleId IdType="pmc">PMC5837163</ArticleId><ArticleId IdType="pubmed">29323105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Wang J., Liu J., Zheng L., Wang W., Huo Y., Sun X. The surface-exposed loop region of norovirus GII.3 VP1 plays an essential role in binding histo-blood group antigens. Arch. Virol. 2019;164(6):1629–1638. doi: 10.1007/s00705-019-04256-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-019-04256-3</ArticleId><ArticleId IdType="pubmed">30968211</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zhao Y., Liu H., Sun H., Huang X., Yang Z., Ma S. Molecular characterization of two novel echovirus 18 recombinants associated with hand-foot-mouth disease. Sci. Rep. 2017;7(1):8448. doi: 10.1038/s41598-017-09038-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09038-y</ArticleId><ArticleId IdType="pmc">PMC5559515</ArticleId><ArticleId IdType="pubmed">28814774</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N., Zheng T., Chen Y., Zhu H., Qu Y., Zheng H., Liu H., Liu Q. Coxsackievirus B5 virus-like particle vaccine exhibits greater immunogenicity and immunoprotection than its inactivated counterpart in mice. Vaccine. 2021;39(39):5699–5705. doi: 10.1016/j.vaccine.2021.07.095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.07.095</ArticleId><ArticleId IdType="pubmed">34420787</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Li H.Y., Han J.F., Deng Y.Q., Zhu S.Y., Li X.F., Yang H.Q., Li Y.X., Zhang Y., Qin E.D., Chen R., Qin C.F. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice. Sci. Rep. 2015;5:7878. doi: 10.1038/srep07878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep07878</ArticleId><ArticleId IdType="pmc">PMC4297979</ArticleId><ArticleId IdType="pubmed">25597595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Liu X., Wu Y., He Y., Zheng H., Liu H., Liu Q. Identification of a neutralizing linear epitope within the VP1 protein of coxsackievirus A10. Virol. J. 2022;19(1):203. doi: 10.1186/s12985-022-01939-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01939-3</ArticleId><ArticleId IdType="pmc">PMC9714398</ArticleId><ArticleId IdType="pubmed">36457099</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu P., Ji W., Li D., Li Z., Chen Y., Dai B., Han S., Chen S., Jin Y., Duan G. Current status of hand-foot-and-mouth disease. J. Biomed. Sci. 2023;30(1):15. doi: 10.1186/s12929-023-00908-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-023-00908-4</ArticleId><ArticleId IdType="pmc">PMC9951172</ArticleId><ArticleId IdType="pubmed">36829162</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>